High free fatty acids level related with cardiac dysfunction in obese rats

Diabetes Research and Clinical Practice

Volumn 95, Issue 2, 2012, Pages 251-259

  Sun, Xiaodong ^a   Pan, Hua ^a   Tan, Huiwen ^a   Yu, Yerong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Cytochrome C; INOS; Mitochondrion; Myocardial dysfunction; NF B; Obesity

Indexed keywords

ANGIOTENSIN II; CYTOCHROME C; FATTY ACID; FENOFIBRATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; TRIACYLGLYCEROL;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DIASTOLE; DRUG MECHANISM; ENZYME RELEASE; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; HEART CONTRACTION; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART MITOCHONDRION; HEART MUSCLE; HEART MUSCLE DP-DT; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; LIPID DIET; LIPID STORAGE; MALE; NONHUMAN; OBESITY; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TISSUE LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANGIOTENSIN II; ANIMALS; BIOLOGICAL MARKERS; DIET, HIGH-FAT; FATTY ACIDS, NONESTERIFIED; FENOFIBRATE; HEART FAILURE; IMMUNOHISTOCHEMISTRY; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; OBESITY; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RENIN-ANGIOTENSIN SYSTEM; TRIGLYCERIDES;

EID: 84856400955     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.10.028     Document Type: Article

References (32)

1. Marinou K., Tousoulis D., Antonopoulos A.S., Stefanadi E., Stefanadis C. Obesity and cardiovascular disease: from pathophysiology to risk stratification. Int J Cardiol 2010, 138:3-8.
2. Morse S.A., Gulati R., Reisin E. The obesity paradox and cardiovascular disease. Curr Hypertens Rep 2010, 12:120-126.
3. Loehr L.R., Rosamond W.D., Poole C., McNeill A.M., Chang P.P., Deswal A., et al. The potentially modifiable burden of incident heart failure due to obesity: the atherosclerosis risk in communities study. Am J Epidemiol 2010.
4. Nicklas B.J., Cesari M., Penninx B.W., Kritchevsky S.B., Ding J., Newman A., et al. Abdominal obesity is an independent risk factor for chronic heart failure in older people. J Am Geriatr Soc 2006, 54:413-420.
5. Lakhani M., Fein S. Effects of obesity and subsequent weight reduction on left ventricular function. Cardiol Rev 2011, 19:1-4.
6. Coviello J.S., Nystrom K.V. Obesity and heart failure. J Cardiovasc Nurs 2003, 18:360-366. quiz 367-8.
7. Chirinos J.A., Segers P., De Buyzere M.L., Kronmal R.A., Raja M.W., De Bacquer D., et al. Left ventricular mass: allometric scaling, normative values, effect of obesity, and prognostic performance. Hypertension 2010, 56:91-98.
8. Rider O.J., Francis J.M., Ali M.K., Byrne J., Clarke K., Neubauer S., et al. Determinants of left ventricular mass in obesity; a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson 2009, 11:9.
9. Kardassis D., Bech-Hanssen O., Schonander M., Sjostrom L., Petzold M., Karason K. Impact of body composition, fat distribution and sustained weight loss on cardiac function in obesity. Int J Cardiol 2011.
10. Frohlich E.D., Susic D. Mechanisms underlying obesity associated with systemic and renal hemodynamics in essential hypertension. Curr Hypertens Rep 2008, 10:151-155.
11. Buchanan J., Mazumder P.K., Hu P., Chakrabarti G., Roberts M.W., Yun U.J., et al. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005, 146:5341-5349.
12. Aasum E., Khalid A.M., Gudbrandsen O.A., How O.J., Berge R.K., Larsen T.S. Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice. J Mol Cell Cardiol 2008, 44:201-209.
13. Mazumder P.K., O'Neill B.T., Roberts M.W., Buchanan J., Yun U.J., Cooksey R.C., et al. Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 2004, 53:2366-2374.
14. Schaffer J.E., Lipotoxicity: When tissues overeat. Curr Opin Lipidol 2003, 14:281-287.
15. Ke L., Yu Y.R., Zhang X.E., Zhang X.X., Lu Z.M. The effect and pathophysiological mechanism of high free fatty acids (FfAs) on the cardiac structure and function. Sichuan Da Xue Xue Bao Yi Xue Ban 2009, 40:24-28.
16. Zhou Y.T., Grayburn P., Karim A., Shimabukuro M., Higa M., Baetens D., et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 2000, 97:1784-1789.
17. Peterson L.R., Herrero P., McGill J., Schechtman K.B., Kisrieva-Ware Z., Lesniak D., et al. Fatty acids and insulin modulate myocardial substrate metabolism in humans with type 1 diabetes. Diabetes 2008, 57:32-40.
18. Young M.E., Guthrie P.H., Razeghi P., Leighton B., Abbasi S., Patil S., et al. Impaired long-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. Diabetes 2002, 51:2587-2595.
19. Lin K.T., Xue J.Y., Nomen M., Spur B., Wong P.Y. Peroxynitrite-induced apoptosis in HL-60 cells. J Biol Chem 1995, 270:16487-16490.
20. Pu S., Yu Y.R., Lu Z.M. Effect of inflammation factors on endothelial function in insulin resistance SD rats. Sichuan Da Xue Xue Bao Yi Xue Ban 2010, 41. 398-402, 419.
21. Sun X., Han F., Yi J., Han L., Wang B. Effect of aspirin on the expression of hepatocyte NF-kappaB and Serum TNF-alpha in streptozotocin-induced type 2 diabetic rats. J Korean Med Sci 2011, 26:765-770.
22. Feuerstein G., Yue T.L., Ma X., Ruffolo R.R. Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol. Prog Cardiovasc Dis 1998, 41:17-24.
23. Purcell N.H., Tang G., Yu C., Mercurio F., DiDonato J.A., Lin A. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci USA 2001, 98:6668-6673.
24. Ha T., Li Y., Gao X., McMullen J.R., Shioi T., Izumo S., et al. Attenuation of cardiac hypertrophy by inhibiting both mTOR and NFkappaB activation in vivo. Free Radic Biol Med 2005, 39:1570-1580.
25. Kan H., Xie Z., Finkel M.S. TNF-alpha enhances cardiac myocyte NO production through MAP kinase-mediated NF-kappaB activation. Am J Physiol 1999, 277:H1641-H1646.
26. Piro S., Anello M., Di P.C., Lizzio M.N., Patane G., Rabuazzo A.M., et al. Chronic exposure to free fatty acids or high glucose induces apoptosis in rat pancreatic islets: possible role of oxidative stress. Metabolism 2002, 51:1340-1347.
27. Bhatia V., Bhatia R., Mathew B. Angiotensin receptor blockers in congestive heart failure: evidence, concerns, and controversies. Cardiol Rev 2005, 13:297-303.
28. Verdecchia P., Angeli F., Cavallini C., Gattobigio R., Gentile G., Staessen J.A., et al. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. Eur Heart J 2009, 30:679-688.
29. Guo X., Saini H.K., Wang J., Gupta S.K., Goyal R.K., Dhalla N.S. Prevention of remodeling in congestive heart failure due to myocardial infarction by blockade of the renin-angiotensin system. Expert Rev Cardiovasc Ther 2005, 3:717-732.
30. Ainscough J.F., Drinkhill M.J., Sedo A., Turner N.A., Brooke D.A., Balmforth A.J., et al. Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction. Cardiovasc Res 2009, 81:592-600.
31. Dostal D.E. The cardiac renin-angiotensin system: novel signaling mechanisms related to cardiac growth and function. Regul Pept 2000, 91:1-11.
32. Serneri G.G., Boddi M., Cecioni I., Vanni S., Coppo M., Papa M.L., et al. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ Res 2001, 88:961-968.